Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dolasetron
Drug ID BADD_D00702
Description Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Indications and Usage For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses of chemotherapy. Also used for the prevention of postoperative nausea and vomiting. This drug can be used intravenously for the treatment of postoperative nausea and vomiting.
Marketing Status Discontinued
ATC Code A04AA04
DrugBank ID DB00757
KEGG ID D07867
MeSH ID C060344
PubChem ID 60654
TTD Drug ID D00YLW
NDC Product Code Not Available
Synonyms dolasetron | 1H-indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, (2-alpha,6-alpha,8-alpha,9a-beta)- | octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl 1H-indole-3-carboxylate | indole-3-carboxylic acid, ester with (8R)-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one | dolasetron mesylate | dolasetron mesylate monohydrate | 1H-indole-3-carboxylic acid-trans-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester methanesulfonate | dolasetron mesilate monohydrate | 1H-indole-3-carboxylic acid, (6R,9AS)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, rel-, methanesulfonate, hydrate (1:1:1) | Anzemet | MDL 73,147EF | MDL-73147EF | MDL 73147EF
Chemical Information
Molecular Formula C19H20N2O3
CAS Registry Number 115956-12-2
SMILES C1C2CC3CC(CC1N3CC2=O)OC(=O)C4=CNC5=CC=CC=C54
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pruritus23.03.12.001--
Pulmonary congestion24.03.08.001; 22.01.03.002; 02.05.02.002--Not Available
Purpura01.01.04.003; 24.07.06.005; 23.06.01.004--
Rash23.03.13.001--Not Available
Seizure17.12.03.001--
Sepsis11.01.11.003--
Shock24.06.02.002--Not Available
Sinus arrhythmia02.03.03.008--Not Available
Sleep disorder19.02.04.001--Not Available
Sneezing22.02.05.011--
Somnolence19.02.05.003; 17.02.04.006--
Stomatitis07.05.06.005--
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Tachycardia02.03.02.007--Not Available
Throat irritation07.05.03.004; 22.02.05.013--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tremor17.01.06.002--
Urinary retention20.02.02.011--
Urticaria10.01.06.001; 23.04.02.001--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Ventricular arrhythmia02.03.04.006--
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Vertigo04.04.01.003; 17.02.12.002--
Visual impairment06.02.06.008--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Respiratory tract congestion22.02.07.003--Not Available
Nasal discomfort22.02.05.020--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages